434P - The evaluation of lung cancer patients treated with EGFR-TKI gefitinib as first-line treatment: The Indonesian experience

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Non-Small-Cell Lung Cancer, Metastatic
Presenter Anna Febriani
Citation Annals of Oncology (2016) 27 (suppl_9): ix136-ix138. 10.1093/annonc/mdw593
Authors L. Wulandari1, A. Febriani1, F.F. Wati1, G. Soegiarto2
  • 1Pulmonology And Respiratory Medicine, Dr. Soetomo Hospital-Airlangga University Medical School, 60286 - Surabaya/ID
  • 2Internal Medicine, Dr. Soetomo Hospital-Airlangga University Medical School, 60286 - Surabaya/ID



Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the standard therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Gefitinib is the first EGFR-TKI marketed in Indonesia and had been used since 2012 in Dr. Soetomo Hospital, a tertiary hospital in Surabaya, East Java. Although the drug had shown some positive results, the overall treatment outcome for Indonesian patients has not been reported yet. The aim of this study is to evaluate the objective and subjective response of gefitinib as first-line treatment in advanced EGFR-mutated NSCLC patients in Dr. Soetomo Hospital.


This retrospective study includes all eligible patients treated from 2013 to 2016. All demographic data, performance status, tumor histopathologic types, treatment response, and all of the adverse effects (AE’s) during the course of treatment were collected from patient’s medical records. Objective response was based on RECIST 1.1. Progression free survival (PFS) and overall survival (OS) were calculated.


Of 70 patients eligible for this study, 40 patient’s data (57%) were available for present analysis. Most patients were female (57.5%) with median age of 58 years (range 33- 77 years), and mostly non-smokers (62.5%). Thirty three patients (82.5%) had stage IV disease. Most patients had PS 1 (77.5%). Adenocarcinoma was the most prevalent histopathology. Median PFS was 7 months (range 2-19 months), while median OS was 10 months (range 3-27 months). Common AE’s reported were skin rash (72.5%), diarrhea (50%), nausea and vomiting (32.5%), paronychia (20%), and acne (12.5%). None of them lead to dose reduction or drug discontinuation.


In Indonesian patients with EGFR-mutated NSCLC, gefitinib showed favourable objective response and was generally well tolerated.

Clinical trial indentification

NCT 02755337

Legal entity responsible for the study

Dr. Soetomo General Hospital, Surabaya, Indonesia


Astra Zeneca


A. Febriani: Received external sponsor research funding from Astra Zeneca. L. Wulandari: Received external sponsor research funding from Astra Zeneca. All other authors have declared no conflicts of interest.